FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

Number 5: Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Starjemza gains FDA approval as the eighth ustekinumab biosimilar, enhancing treatment options for rheumatic and ...

There's a need for early anti-tumor necrosis factor (TNF) therapy in inflammatory bowel disease (IBD), with new data showing ...

Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the ...

In conclusion, the 2025 CDSCO draft guidelines represent a meaningful and commendable step toward global regulatory alignment ...

Eculizumab biosimilars could provide European patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic ...

Elena Wolff-Holz, MD, discussed the rationale and safety surrounding the automatic substitution of biosimilars at the pharmacy level, as well as common misconceptions about these medications. Elena ...